Desoxyn

Obesity, Narcolepsy, Attention Deficit Hyperactivity Disorder

Treatment

3 FDA approvals

20 Active Studies for Desoxyn

What is Desoxyn

Metamfetamine

The Generic name of this drug

Treatment Summary

Metamfetamine (also known as methamphetamine) is a stimulant drug that causes a high feeling, increased alertness and energy, and increased self-esteem. It is a member of the amphetamine group of drugs and is highly addictive and dangerous, so it is classified as a controlled substance in most countries.

Desoxyn

is the brand name

image of different drug pills on a surface

Desoxyn Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Desoxyn

Metamfetamine

1943

8

Approved as Treatment by the FDA

Metamfetamine, commonly known as Desoxyn, is approved by the FDA for 3 uses including refractory exogenous obesity and Attention Deficit Hyperactivity Disorder .

refractory exogenous obesity

Helps manage refractory exogenous obesity

Attention Deficit Hyperactivity Disorder

Helps manage Attention Deficit Hyperactivity Disorder (ADHD)

Obesity

Helps manage refractory exogenous obesity

Effectiveness

How Desoxyn Affects Patients

Methamphetamine is a stimulant that affects many of the body's regulatory functions, including heart rate, body temperature, blood pressure, appetite, and alertness. Taking the drug can cause a "fight-or-flight" response in the body, with an increased heart rate, constricted blood vessels, increased breathing, and increased blood sugar. Users of methamphetamine may have improved focus and alertness, and experience decreased fatigue and appetite.

How Desoxyn works in the body

Methamphetamine enters the brain and stimulates the release of chemicals like norepinephrine, dopamine and serotonin. It also prevents these chemicals from being reabsorbed in the brain, which can lead to increased activity in certain areas. The exact way that methamphetamine produces the positive behavioral changes seen in hyperactive children is still a mystery.

When to interrupt dosage

The proposed measure of Desoxyn is predicated upon the diagnosed affliction, including Attention Deficit Hyperactivity Disorder, refractory exogenous obesity and Narcolepsy. The dosage varies, in relation to the method of delivery (e.g. Tablet or Oral) delineated in the table underneath.

Condition

Dosage

Administration

Narcolepsy

, 5.0 mg

, Oral, Tablet, Tablet - Oral

Attention Deficit Hyperactivity Disorder

, 5.0 mg

, Oral, Tablet, Tablet - Oral

Obesity

, 5.0 mg

, Oral, Tablet, Tablet - Oral

Warnings

Desoxyn Contraindications

Condition

Risk Level

Notes

Hyperthyroidism

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

advanced arteriosclerosis

Do Not Combine

Agitation

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Open-angle glaucoma

Do Not Combine

Drug abuse

Do Not Combine

There are 20 known major drug interactions with Desoxyn.

Common Desoxyn Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Metamfetamine.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Metamfetamine.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Metamfetamine.

Ethanol

Major

Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Desoxyn Toxicity & Overdose Risk

Signs of methamphetamine overdose include restlessness, shaking, increased reflexes, fast breathing, confusion, aggressive behavior, hallucinations, panic attacks, high body temperature, and muscle breakdown. After the initial stimulation, patients often feel tired and depressed. Cardiovascular problems include abnormal heart rhythms, high or low blood pressure, and circulatory failure. Other symptoms include nausea, vomiting, diarrhea, and stomach cramps. Severe overdoses can lead to seizures and coma before death.

image of a doctor in a lab doing drug, clinical research

Desoxyn Novel Uses: Which Conditions Have a Clinical Trial Featuring Desoxyn?

At present, 84 active trials are exploring the possible benefits of Desoxyn in refractory exogenous obesity, Attention Deficit Hyperactivity Disorder and Narcolepsy.

Condition

Clinical Trials

Trial Phases

Obesity

0 Actively Recruiting

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Desoxyn Reviews: What are patients saying about Desoxyn?

5

Patient Review

5/18/2019

Desoxyn for Attention Deficit Disorder with Hyperactivity

I've tried a lot of different treatments for ADD, and by far I found Desoxyn to be the best. Not only did it help with my attention deficit, but also with depression and my eating disorder. I've been taking it for 25 years now without any negative side effects.

5

Patient Review

4/28/2011

Desoxyn for Attention Deficit Disorder with Hyperactivity

For those who have used methamphetamine for a long time and can't imagine living without it, this drug could be life-changing. Given by a doctor who understands addiction and weighs the risks, this government-approved meth could be a much safer option than street drugs.

5

Patient Review

5/17/2010

Desoxyn for Attention Deficit Disorder with Hyperactivity

5

Patient Review

1/25/2011

Desoxyn for Attention Deficit Disorder with Hyperactivity

4.7

Patient Review

6/30/2011

Desoxyn for Attention Deficit Disorder with Hyperactivity

I have tried nearly every stimulant on the market, from Adderall to Vyvanse. After months of taking them with little to no results (and some nasty side effects), I finally found a medication that works for me. I've been on it for five years and have only needed two dose adjustments.

4.7

Patient Review

1/18/2011

Desoxyn for Overweight

4

Patient Review

10/29/2012

Desoxyn for Attention Deficit Disorder with Hyperactivity

I tried this treatment a while ago and it worked well, but then my insurance changed and I had to switch to something else.

4

Patient Review

2/5/2015

Desoxyn for Attention Deficit Disorder with Hyperactivity

This drug is great. It's the only one that makes me feel like a normal human being.

4

Patient Review

10/4/2011

Desoxyn for Attention Deficit Disorder with Hyperactivity

This treatment was helpful to me many years ago.

3

Patient Review

6/26/2013

Desoxyn for Attention Deficit Disorder with Hyperactivity

This treatment is effective, but it didn't completely remove my overall body pain. It lasts for 4 to 8 hours, which is helpful, but I would like to see it be more long-lasting.

3

Patient Review

5/17/2013

Desoxyn for Attention Deficit Disorder with Hyperactivity

This was a helpful drug with no noted negative side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about desoxyn

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Desoxyn expensive?

"Methamphetamine, or Desoxyn, is a drug used to treat attention-deficit hyperactivity disorder, though it is less popular than comparable drugs. It may also be used in the short-term treatment of obesity when combined with diet and exercise."

Answered by AI

What do they prescribe Desoxyn for?

"This medication is used to treat ADHD by changing the amounts of certain natural substances in the brain."

Answered by AI

What is the generic name of Desoxyn?

"Desoxyn is a medication used to treat ADHD symptoms in children, adolescents, and adults. It is an immediate-release, stimulant medication that may help improve focus and decrease impulsivity and hyperactive behavior."

Answered by AI

Is Desoxyn still prescribed?

"The only legal meth product is Desoxyn®, which is only available through a prescription that cannot be refilled."

Answered by AI

Clinical Trials for Desoxyn

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Desoxyn clinical trials?

We made a collection of clinical trials featuring Desoxyn, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Desoxyn clinical trials?

We made a collection of clinical trials featuring Desoxyn, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Desoxyn clinical trials?

We made a collection of clinical trials featuring Desoxyn, we think they might fit your search criteria.
Go to Trials